Chaves Sandra S, Zhang John, Civen Rachel, Watson Barbara M, Carbajal Tina, Perella Dana, Seward Jane F
Centers for Disease Control and Prevention, Atlanta, Georgia 30332, USA.
J Infect Dis. 2008 Mar 1;197 Suppl 2:S127-31. doi: 10.1086/522150.
Approximately 1 in every 5 children who receives 1 dose of varicella vaccine may develop varicella disease, also known as breakthrough disease, if exposed to varicella-zoster virus. Currently, in communities with high vaccination coverage, varicella cases mostly occur in vaccinated individuals. We report on the first population-based description of the clinical and epidemiological characteristics of varicella in populations with increasing vaccine coverage between 1997 and 2005. In vaccinated children 1-14 years of age, varicella was most often mild and modified; the atypical disease presentation may result in diagnostic challenges to health care providers. However, despite the generally mild nature of these cases, approximately 25% caused >50 lesions, and some resulted in serious complications similar to those occurring in unvaccinated individuals. Continued surveillance of the risk and characteristics of breakthrough disease will be needed, to monitor the effect of the new 2-dose vaccine recommendation for children.
每5名接种1剂水痘疫苗的儿童中,约有1名若接触水痘-带状疱疹病毒,可能会患上水痘疾病,即所谓的突破性疾病。目前,在疫苗接种覆盖率高的社区,水痘病例大多发生在已接种疫苗的个体中。我们报告了1997年至2005年间疫苗接种覆盖率不断提高的人群中水痘临床和流行病学特征的首次基于人群的描述。在1至14岁接种疫苗的儿童中,水痘通常最为轻微且症状有所减轻;非典型的疾病表现可能给医疗服务提供者带来诊断挑战。然而,尽管这些病例总体症状较轻,但约25%的病例出现了超过50处皮疹,有些还导致了与未接种疫苗个体类似的严重并发症。需要持续监测突破性疾病的风险和特征,以监测针对儿童的新的2剂疫苗推荐的效果。